Ligand validation:8IGB

UED: N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide

UED is a Ligand Of Interest in 8IGB designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8IGB_UED_B_401	60%	20%	0.115	0.901	1.98	1.4	2	6	0	0	100%	1
8IGB_UED_A_401	57%	22%	0.12	0.896	1.82	1.44	2	6	0	0	100%	1
8FIG_UED_A_401	81%	53%	0.108	0.96	0.69	1.13	-	2	0	0	100%	0.51
7JSU_UED_A_401	78%	38%	0.086	0.928	1.25	1.19	3	3	0	0	100%	1
7LCP_UED_A_401	62%	10%	0.13	0.922	2.78	1.58	8	7	0	0	100%	1
8IG4_UED_B_401	62%	19%	0.118	0.909	1.88	1.56	2	8	0	0	100%	1
8IG9_UED_B_401	59%	5%	0.112	0.892	3.13	2.3	10	11	0	0	100%	1
7SNA_UED_A_401	74%	6%	0.121	0.951	3.66	1.58	16	9	0	0	100%	1
7SMV_UED_B_401	68%	3%	0.124	0.934	4.33	1.93	10	10	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.